Raised calcium promotes α-synuclein aggregate formation

[1]  Jason T Giurleo,et al.  In vitro formation of amyloid from alpha-synuclein is dominated by reactions at hydrophobic interfaces. , 2010, Journal of the American Chemical Society.

[2]  Yves Engelborghs,et al.  Early aggregation steps in alpha-synuclein as measured by FCS and FRET: evidence for a contagious conformational change. , 2010, Biophysical journal.

[3]  V. Subramaniam,et al.  A stable lipid-induced aggregate of alpha-synuclein. , 2010, Journal of the American Chemical Society.

[4]  J. Rochet,et al.  Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies. , 2010, The journal of physical chemistry. B.

[5]  Carol D. Hicks,et al.  Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent α-Synuclein Oligomer Formation and Rescue α-Synuclein-Induced Toxicity , 2010, Journal of Pharmacology and Experimental Therapeutics.

[6]  J. Olzmann,et al.  Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. , 2010, Biochemical Society transactions.

[7]  D. Surmeier,et al.  Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease. , 2010, Cell calcium.

[8]  R. Nicoll,et al.  Increased Expression of α-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis , 2010, Neuron.

[9]  G. Wenning,et al.  Multiple system atrophy: an update , 2009, The Lancet Neurology.

[10]  M. Dallas,et al.  α‐Synuclein modulation of Ca2+ signaling in human neuroblastoma (SH‐SY5Y) cells , 2009, Journal of neurochemistry.

[11]  Enikö Kövari,et al.  Proteomics in human Parkinson's disease research. , 2009, Journal of proteomics.

[12]  Michael Wolff,et al.  Seeding induced by α‐synuclein oligomers provides evidence for spreading of α‐synuclein pathology , 2009, Journal of neurochemistry.

[13]  Vladimir N Uversky,et al.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. , 2009, Current protein & peptide science.

[14]  K. Jellinger,et al.  Formation and development of Lewy pathology: a critical update , 2009, Journal of Neurology.

[15]  V. Uversky.  Intrinsic Disorder in Proteins Associated with Neurodegenerative Diseases , 2009 .

[16]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[17]  Jason D. Perlmutter,et al.  Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: molecular simulations of the micelle- and bilayer-bound forms. , 2009, The Journal of biological chemistry.

[18]  M. Cookson.  α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[19]  Seung-Jae Lee,et al.  Controlling the mass action of α‐synuclein in Parkinson’s disease , 2008, Journal of neurochemistry.

[20]  C. Griesinger,et al.  Site-specific interactions of Cu(II) with alpha and beta-synuclein: bridging the molecular gap between metal binding and aggregation. , 2008, Journal of the American Chemical Society.

[21]  T. Lazaridis,et al.  Membrane‐bound structure and energetics of α‐synuclein , 2008 .

[22]  Armin Giese,et al.  Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding , 2007, The Journal of Neuroscience.

[23]  M. Mattson,et al.  Calcium and neurodegeneration , 2007, Aging cell.

[24]  Julia Thom Oxford,et al.  Calpain-Cleavage of α-Synuclein : Connecting Proteolytic Processing to Disease-Linked Aggregation , 2007 .

[25]  V. Uversky,et al.  Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. , 2006, Biochemistry.

[26]  A. Young,et al.  Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Shults.  Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  X. Shen,et al.  SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy , 2005, Neuroscience Letters.

[29]  C. Dobson,et al.  Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[30]  N. Voelcker,et al.  Calcium(II) selectively induces α‐synuclein annular oligomers via interaction with the C‐terminal domain , 2004, Protein science : a publication of the Protein Society.

[31]  M. Chesselet,et al.  Alpha-synuclein and transgenic mouse models , 2004, Neurobiology of Disease.

[32]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[33]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[34]  Sebastian Doniach,et al.  Biophysical Properties of the Synucleins and Their Propensities to Fibrillate , 2002, The Journal of Biological Chemistry.

[35]  H. Vorum,et al.  Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.

[36]  B. Hyman,et al.  α-Synuclein–enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons , 2001, Neuroscience.

[37]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[38]  P. Lansbury,et al.  Accelerated Oligomerization by Parkinson's Disease Linked α‐Synuclein Mutants , 2000 .

[39]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[40]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[41]  P. Mcgeer,et al.  Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K , 1990, Brain Research.

[42]  T. Dawson,et al.  The role of parkin in familial and sporadic Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[43]  N. Voelcker,et al.  Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis , 2009, Neurotoxicity Research.